AbbVie Reports Results of Rinvoq (upadacitinib) P-III (U-ENDURE) Maintenance Study for the Treatment of Crohn's Disease
Shots:
- The P-III (U-ENDURE) study evaluate upadacitinib (15/30mg, qd) vs PBO as maintenance therapy in 673 patients with CD with inadequate response or who were intolerant to a conventional or biologic therapy
- The results showed that patients achieved clinical remission per CDAI @52wk. (37% & 48% vs 15%); clinical remission per SF/AP (36% & 46% vs 14%); endoscopic response (28% & 40% vs 7%); endoscopic remission (19% & 29% vs 5%) & corticosteroid-free clinical remission/CDAI & SF/AP
- The safety results were consistent with the P-III induction studies, no new safety risks with no thrombotic events & no deaths were reported. Future regulatory filings will contain the results of the (U-ENDURE), (EXCEED) & (U-EXCEL) studies
Ref: PRNewswire | Image: AbbVie
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
